Frank Theobald | Vice President, Head MAP Program
LTS Lohmann Therapie-Systeme AG

Frank Theobald drives the strategic evolution of microneedle technology as Corporate Vice President and Head of the MAP Program at LTS. With nearly three decades in formulation development and project leadership, he transforms complex ideas into market‑ready drug‑delivery solutions. Frank shapes LTS’s global MAP strategy, accelerates innovative development pipelines, and forges impactful collaborations with academia and industry. His work positions MAPs as a disruptive technology redefining patient‑centric delivery. Frank graduated from the University of the Saarland in Pharmacy and received his PhD in Pharmaceutical Technology from the same University in 1997.

Appearances:

Pre-Congress Workshops (19th October) @ 14:15

Panel: From Non-Inferiority to Impact: Accelerating Adoption of Needle-Free Vaccine Delivery

Are you intrigued by new delivery technologies, but you are reluctant to adopt in your program because you currently assume:

Needles are good enough
there is not enough real-world evidence to support its efficacy
the regulatory pathway will be difficult
the delivery technology is not compatible with your therapy
patient adoption will be difficult
it is too risky or costly to integrate the technology into your pipeline

Come and learn why these assumptions are mostly outdated, and why now, more than ever, several new technologies may provide you with the advantage you need for enhanced efficacy and patient adoption of your therapeutic or vaccine product.

Moderator: Joe Keenan, Director of Regulatory & Commercial Strategy, Daicel